How is mycoplasma pneumonia treated?

Mycoplasma pneumoniae is a common pathogenic microorganism, and in the past, it was thought that Mycoplasma was not very pathogenic, and most of them improved on their own. In recent years, many severe Mycoplasma pneumoniae pneumonia have been found in clinical work, and the number of refractory Mycoplasma pneumoniae pneumonia and Mycoplasma macrolide drug-resistant pneumonia has been increasing, which has brought challenges to clinical work.

mycoplasma

The infection of mycoplasma pneumonia is global, sporadic throughout the year, and can also break out, with a certain degree of contagion, and there is an incubation period of 1~3 weeks after infection. In recent years, the incidence of mycoplasma infection has gradually increased, accounting for about 1/3 of respiratory diseases, and has gradually become the cause of hospitalization for community-acquired pneumonia.Mycoplasma pneumonia can occur in infants and even neonates, with a high incidence in preschool and school-age children.

Chest x-ray is necessary

Treatment of mycoplasma pneumonia begins with choosing the right antibiotic. Erythromycin is the first choice, and the dose is 30~50mg/kd.d, which can be oral or intravenous. If azithromycin is used, take it for three days and stop for four days, and the dose is 10 mg/kg.d. The conventional sequential treatment regimen is intravenous erythromycin for 5~7 days, and then azithromycin is used orally. The total course of treatment is 3~4 weeks or longer. Azithromycin can be used for erythromycin resistance, and new macrolides such as thiomycin can be used for azithromycin resistance. Corticosteroids and gamma globulin or bronchoscopic lavage if necessary.